Released Nov 7, 2017, after the close
10-Q filed Nov 7, 2017, 38 days after period end · 0001232524-17-000179
Q3 2017 · 10-Q
Revenue$411.86M$411.86M +10.1% vs Q3 2016+4.4% vs Q2 2017
Net Income$63.53M$63.53M −29.3% vs Q3 2016−39.8% vs Q2 2017
EPS Diluted$1.03$1.03 −29.0% vs Q3 2016−40.1% vs Q2 2017
Gross Profit$376,768,000+8.5%
Operating Income$86,454,000−36.5%
Operating Cash Flowderived$188,897,000+42.0%
Free Cash Flowderived$180,550,000+38.2%
Margins · derived
Gross margin91.5%−1.3 pt vs Q3 2016
Operating margin21.0%−15.4 pt vs Q3 2016
Net margin15.4%−8.6 pt vs Q3 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Revenue | $411.86M | $374.18M | $340.87M | $306.58M |
| Net Income | $63.53M | $89.83M | $87.96M | $25.77M |
| EPS Diluted | $1.03 | $1.45 | $1.39 | $0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR